Horizon Therapeutics (HZNP) PT Raised to $115 at BMO Capital

February 22, 2021 12:08 AM EST
Get Alerts HZNP Hot Sheet
Price: $91.48 +0.53%

Rating Summary:
    15 Buy, 3 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 17 | Down: 14 | New: 42
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

BMO Capital analyst Gary Nachman raised the price target on Horizon Therapeutics (NASDAQ: HZNP) to $115.00 (from $110.00) while maintaining a Outperform rating.

The analyst comments "We updated our HZNP model incorporating VIE acquisition announced 2/1, and recent comments on opex and Tepezza/Krystexxa trends (exceeded 2020 guidance), including near-term Tepezza supply disruption. We also include feedback from three ophthalmologists we recently spoke with that help confirm a very strong Tepezza outlook, including potential in chronic/fibrotic TED (Ph4 starting 2Q21). Physicians are closely monitoring patients disrupted by Tepezza supply disruption and expect to queue most new patients for treatment (optimistic on near-term resolution), which should support strong ramp starting 2Q21. Reiterate Outperform; target to $115 from $110."



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst PT Change

Related Entities

BMO Capital, Definitive Agreement